Regeneron Pharmaceuticals's operating margin was 24.9% for fiscal year 2025 (the twelve months to 31 Dec 2025), down 3.2 points from fiscal 2024.
In the third quarter of fiscal 2026 (the three months to 30 Sep 2026) it was 40.0%, up 12.7 points from a year earlier.
From Regeneron Pharmaceuticals's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 30 Oct 2026.
Fiscal 2025
24.9%
−3.2 pts
Q3 FY2026
40.0%
+12.7 pts on a year
Average over 10 years
36.6%
FY 2016–FY 2025
Operating margin by fiscal year
Change in points on the year before, under each year. From FY 2016 to FY 2025, Regeneron Pharmaceuticals's operating margin went from 27.4% to 24.9%; the highest was 55.7% in FY 2021.
Regeneron Pharmaceuticals operating margin, fiscal years
Period
FY 2016
FY 2017
FY 2018
FY 2019
FY 2020
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Operating margin
27.4%
35.4%
49.3%
33.7%
42.1%
55.7%
38.9%
30.9%
28.1%
24.9%
Period end
31 Dec 2016
31 Dec 2017
31 Dec 2018
31 Dec 2019
31 Dec 2020
31 Dec 2021
31 Dec 2022
31 Dec 2023
31 Dec 2024
31 Dec 2025
Operating margin by quarter
The last eight fiscal quarters. Each is compared with the same quarter a year earlier on the company's page.
Operating margin is operating income divided by revenue. Figures are read from the report the company filed and checked against accounting identities; one that does not pass is left blank rather than estimated. See data and methodology.
Regeneron Pharmaceuticals's other figures
Operating margin of comparable companies
Everything on REGN, in the terminal.
Twenty years of history, operating KPIs and segments, guidance against results, valuation, insiders and holders, charts and alerts.